Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Let’s keep the information as real as we can…why not

<< Previous

Bullboard Posts

Next >>

Comment by fox7mfon Apr 23, 2023 12:47pm

100 Views

Post# 35409372

RE:RE:RE:RE:Let’s keep the information as real as we can…why not

Agreed. No options grant for a job poorly done, on the business development side of things. A $10b usd b/o is approximately $145 a share, fully diluted. Explain how Oncy gets to that price tag.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec